Open AccessRole of remdisivir among COVID-19 patient’s recovery.
Author(s) -
Ather Mehmood,
Javaria Malik,
Attiya Hameed Khan,
Wajid Hussain,
Akhtar Ali Bandeshah,
Arsalan Abdullah,
Sehrish Zubair,
Benish Shahzadi,
Abdul Samad Abbasi
Publication year - 2021
Publication title -
the professional medical journal/the professional medical journal
Language(s) - English
Resource type - Journals
eISSN - 2071-7733
pISSN - 1024-8919
DOI - 10.29309/tpmj/2021.28.12.6787
Subject(s) - medicine , covid-19 , observational study , oxygen saturation , retrospective cohort study , university hospital , oxygen therapy , oxygen , single center , anesthesia , pediatrics , virology , outbreak , infectious disease (medical specialty) , chemistry , disease , organic chemistry
Objective: To assess the effect of Remedisvir, its safety Profile, and efficacy among COVID-19 patients. Study Design: Retrospective Observational study. Setting: South East Hospital and Research Center, Islamabad, Pakistan. Period: December 2020 to July 2021. Material & Methods: 100 patients were included in this study who received Remedisvir infusion, day 5, 7, and 10 after admitting the hospital with COVID-19 symptoms. We infuse 200mg I/V Remedisvir in 100cc N/S followed by 100mg I/V daily into 100cc N/S. After infusion, all patients were monitored strictly. Results: The mean age of the patients was (51. 89±15.441). The outcome of Remedisvir showed that 14% improved their condition, 42% discharged with oxygen, 27% discharged without oxygen, and only 17% expired). Remedisvir showed a positive effect at (p≤0.001) among laboratory values and oxygen support category. Conclusion: When patient suffering from COVID-19 symptoms and low oxygen saturation show good clinical outcome treated with Remedisvir. According to the results of our study, it is concluded that, at present Remedisvir remains a good drug, it shows a positive effect on oxygen saturation and length of hospital stay.